WCFR becomes second in state to earn Gold Tier Pediatric Readiness Recognition
WALTON COUNTY, Fla. (WMBB) – The Walton County Fire Rescue has achieved a major milestone in emergency medical care on Thursday.
According to a news release, they are now the second agency in Florida to receive the Florida PEDReady Gold tier recognition for pediatric readiness. This recognition highlights WCFR's commitment to providing the highest standard of care for children in emergencies.
The Florida Prehospital Pediatric Readiness Program was developed in collaboration with the state and national organizations. The goal is to ensure EMS agencies are prepared to care for critically ill and injured children.
The Gold tier represents the highest level of pediatric preparedness. Officials said it recognizes agencies that have dedicated pediatric care coordinators, specialized equipment, and comprehensive training programs for their teams.
'This recognition is a testament to our team's dedication to ensuring that every child in our community receives the best possible emergency care,' Fire Chief Austin Pugh said. 'We are incredibly proud to be the second agency in Florida to achieve this Gold tier status. It reflects our ongoing commitment to excellence and the safety of our youngest patients.'
With this achievement, WCFR continues to set the standard for pediatric emergency care, ensuring children in the community receive the highest level of medical attention when needed the most.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Moleculin Participates in Virtual Investor 'What This Means' Segment
Globally recognized Oncology Key Opinion Leader, Brian Andrew Van Tine, MD, PhD, discusses the positive topline results from the U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) Watch the 'What This Means" segment here HOUSTON, June 11, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it participated in a Virtual Investor 'What This Means' segment. For the segment, Brian Andrew Van Tine, MD, PhD, Professor of Medicine, Washington University School of Medicine, discussed the Company's recently announced positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases ('STS lung mets') (MB-107). The MB-107 trial was a multi-center, open-label, single-arm monotherapy study that in Phase 1B determined the Maximum Tolerable Dose and Recommended Phase 2 Dose ('MTD', 'RP2D' respectively) and safety of Annamycin and in Phase 2 explored the efficacy of Annamycin as a single agent for the treatment of subjects with STS lung mets for which chemotherapy was considered appropriate. For more information about the MB-107 trial visit and reference identifier NCT04887298. The Virtual Investor 'What This Means' segment featuring Moleculin is now available here. About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Forward-Looking StatementsSome of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the release of the initial data on the first 45 subjects in the trial and the Company's ability to reconcile the US and EU protocols with the FDA and EMA, respectively. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. 'Risk Factors' in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775MBRX@
Yahoo
26 minutes ago
- Yahoo
Davids Redefines Mouthwash with Breakthrough Hydroxi™ Formula
The Leading Fluoride Free Oral Care Brand Continues to Deliver Trusted Formulas and Expand Innovation with the Launch of Davids Fresh Breath Mouthwash powered by Hydroxi™ MENIFEE, Calif., June 11, 2025 /PRNewswire/ -- Davids Health Sciences, Inc., the trusted leader in premium oral care, continues to innovate and expand their oral care product lineup. Today, the company announced the launch of its Davids Fresh Breath Mouthwash powered by Hydroxi™, a high-performance, fluoride free and alcohol free formula that delivers long-lasting freshness, gum detox, plaque fighting power, and enamel health, incorporating nano hydroxyapatite (same material your teeth and bones are made of). The new mouthwash marks the latest addition to the Davids Hydroxi™ line of products using their proprietary blend of nano hydroxyapatite with high quality naturally sourced and naturally derived ingredients designed to provide superior enamel repair, sensitivity relief, whitening, and long-lasting freshness without the use of fluoride or harsh chemicals. Davids proprietary Hydroxi™ ingredient material is redefining oral care with its scientifically backed ability to remineralize and strengthen teeth. Hydroxi™ utilizes the only nano hydroxyapatite material approved as safe by the European Scientific Committee on Consumer Safety (SCCS). While other natural oral care brands may use similar sounding ingredients, Davids proprietary Hydroxi™ formula significantly outperforms competitors in independent lab testing. "At Davids, our goal has always been to create the best possible products without compromising on quality ingredients," said Eric Buss, Founder & CEO at Davids. "With Hydroxi™, we've combined advanced dental science with the most effective naturally sourced and naturally derived ingredients to create a superior solution for remineralization, sensitivity relief, and fresh breath, without the risks associated with fluoride." Davids Fresh Breath Mouthwash powered by Hydroxi™ is a natural addition to the Davids line of products which already includes toothpaste, expanding dental floss, bamboo toothbrushes, and tongue scrapers. The new mouthwash products continue Davids dedication to high performance oral care utilizing better for you premium ingredients. The EWG VERIFIED™, Leaping Bunny Certified, vegan, formula safely and effectively freshens breath, detoxifies gums, alleviates dry mouth, and fights plaque and gingivitis. It is also alcohol free, fluoride free, and sulfate free to ensure a gentle yet effective cleanse without the strong burning sensation of traditional alcohol based mouthwashes, while a premium mint oil blend provides long-lasting freshness. The innovation continues with the minimalist amber glass bottle packaging design where sustainability meets minimalism. The eco-friendly refill system cuts down on plastic waste with a concentrated formula that gives 96 uses when mixed with 12 ounces of water. This provides a better experience for both people and the planet. Davids Hydroxi™ Fresh Breath Mouthwash Refill Kit, which includes a 16 fl oz reusable glass bottle and a 4 fl oz refill concentrate, is available on for $15.95. Davids Hydroxi™ Fresh Breath Mouthwash Refill Concentrate is also available for $13.95. For more information, visit or follow @davidsoralcare on social media. About Davids Health Sciences, Health Sciences, Inc. is a pioneer in premium oral care, dedicated to providing advanced, highly effective solutions that are both safe and sustainable. Founded on the principle that oral care products should deliver superior performance without compromising on natural purity, Davids combines cutting-edge dental science with the highest quality naturally sourced and naturally derived ingredients. Davids proprietary Hydroxi™ formulation exemplifies this commitment, setting a new industry benchmark for enamel repair, sensitivity relief, whitening, and freshness, all without fluoride or harsh chemicals. In 2011, Davids founder, Eric David Buss, began a four-year obsession to develop the very best clean ingredient toothpaste after looking into the ingredients being used in the "natural" toothpaste he was using. Through extensive research with industry experts, Buss identified the best naturally sourced and naturally derived ingredients, to safely and effectively brighten teeth and smiles. Committed to transparency and environmental responsibility, many Davids products are EWG VERIFIED™, Leaping Bunny Certified, and vegan, ensuring customers can trust the high standards behind every product. With innovation rooted in scientific rigor and sustainability at its core, Davids continues to redefine what premium oral care can achieve. View original content to download multimedia: SOURCE Davids Health Sciences, Inc. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025
Burlington, Massachusetts--(Newsfile Corp. - June 11, 2025) - Lifordi Immunotherapeutics, Inc., a biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, presented preclinical data on its lead program for LFD-200, an ADC delivering a potent glucocorticoid (GC) directly to immune cells. Results of multiple in vitro and in vivo studies in mice and in non-human primates (NHPs) demonstrated that LFD-200 achieves targeted and sustained delivery of its GC payload to immune cells, resulting in efficacy without systemic toxicity. These data were presented at the European Alliance of Associations for Rheumatology (EULAR) meeting in Barcelona. To view the full announcement, including downloadable images, bios, and more, click here. Click image above to view full announcement. About Lifordi Lifordi Immunotherapeutics, Inc. is leading the way in leveraging the success of antibody-drug conjugates (ADCs) to develop treatments for autoimmune and inflammatory disorders. The Company's lead ADC, LFD-200, has demonstrated efficacy in multiple preclinical disease models by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein (VISTA). Lifordi has also applied its novel drug delivery platform to other diverse payloads, such as small molecules, antisense oligonucleotides (ASOs) and siRNA. As experienced drug developers in immunology and inflammatory diseases, together with expert clinical advisors, a strong partnering track record, and funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture to support initial clinical data, Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, please visit Contacts: Theresa McNeely tmcneely@ Source: Lifordi To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
